Pembrolizumab (Keytruda)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Pembrolizumab (Keytruda), 100 mg per 4 mL vial, solution for IV infusion. Indication: Pembrolizumab, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with MIBC who are ineligible for cisplatin-containing chemotherapy.

Authors

Publication Details

Journal
Canadian Journal of Health Technologies
Published
2026-11-16
DOI
https://doi.org/10.51731/cjht.2026.1568
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pembrolizumab (Keytruda)

CDA-AMC
2 links
Canadian Journal of Health Technologies
Bladder and Urothelial Cancer Treatments
article

Pembrolizumab (Keytruda)

CDA-AMC
article en

Abstract

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Pembrolizumab (Keytruda), 100 mg per 4 mL vial, solution for IV infusion. Indication: Pembrolizumab, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with MIBC who are ineligible for cisplatin-containing chemotherapy.

Canadian Journal of Health TechnologiesVol. 6(11)
Good health and well-being
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon